Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection.

There were no significant differences in allograft survival rates between patients with ABMR alone and those with co-occurrence of ABMR and T cell–mediated rejection or borderline changes, although we observed a slight trend toward earlier occurrence of allograft loss among patients with characteristics of other Banff categories in addition to Banff category 2 ( Figure 2D ).

also in 4,078 other papers